RIPK1 and cancer: At low doses, these complexes are highly cytotoxic for cancer cells inducing a significant loss of cell viability that is partially decreased by Z-VAD (apoptosis inhibitor), but also by Nec-1 (RIPK1 inhibitor) and GSK872 (RIPK3 inhibitor), suggesting that both cell death routines are activated.